The ImmuniPrDx project for product development and marketing of best in class MHC/epitope prediction tools has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 867120.
The ImmuniPrDx project
The project aims to develop a novel T-cell epitope prediction software, called PrDx, which, when combined with currently commercialised reagents and assay services, will represent a very powerful epitope (neoantigen) identification platform.
Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
For further information, please contact:
Stephan Thorgrimsen, CEO